Connect with us

NEWS

Merck’s Post-Keytruda ADC Extends Survival After Immunotherapy Fails

Sac-TMT cut endometrial cancer deaths 32% after PD-1 drugs failed, giving Merck a June 2027 FDA date that still cannot replace Keytruda.

Published

on

Sacituzumab tirumotecan cut the risk of death by 32% versus chemotherapy in advanced endometrial cancer, per Phase 3 results presented October 26. Merck and Kelun-Biotech’s Trop-2 antibody-drug conjugate, also called sac-TMT, was tested in women whose disease had already grown after platinum chemotherapy and a PD-1 or PD-L1 drug, the class that includes Keytruda. The U.S. Food and Drug Administration has accepted a biologics license application with priority review and set a target action date of June 15, 2027.

That filing is Merck’s first Western overall-survival win for the Chinese-origin shot it is building as Keytruda’s U.S. patents run toward 2028. Endometrial cancer is a real gap after immunotherapy. It is also a far smaller ledger than the franchise sac-TMT is being asked to help replace.

A 6.9-Month Survival Gain After Chemo and PD-1 Drugs Failed

Domenica Lorusso, professor of obstetrics and gynecology at Humanitas University in Milan and the trial’s global lead investigator, presented TroFuse-005, also coded ENGOT-en23 and GOG-3095, in a Presidential Symposium at the European Society for Medical Oncology Congress in Madrid as late-breaking abstract LBA11. The same dataset was published simultaneously in The Lancet. Merck said the study is the first global Phase 3 trial of a Trop-2 ADC, and the first ADC in this setting, to beat chemotherapy on both overall survival and progression-free survival.

The open-label trial randomized 776 patients in TroFuse-005 1:1 to sac-TMT at 4 mg/kg into a vein every two weeks (386 patients) or to a doctor’s choice of doxorubicin 60 mg/m² every three weeks or paclitaxel 80 mg/m² on days 1, 8, and 15 of a four-week cycle (390 patients). Everyone had already received platinum and anti-PD-1 or PD-L1 therapy, together or in sequence, and no more than three prior lines of systemic treatment. Dual primary endpoints were overall survival and progression-free survival by blinded independent review. This first interim look was also the final formal analysis of those endpoints and of response rate.

TROFUSE-005 EFFICACY AT 14.0 MONTHS

Endpoint Sac-TMT (n=386) Chemo (n=390) Effect
Median overall survival 19.0 months 12.1 months HR 0.68; 32% lower death risk
Median progression-free survival 7.2 months 3.9 months HR 0.59; 41% lower progression or death
Confirmed response rate 35.1% 17.3% +17.8 percentage points
Complete responses 6.1% 4.5% –
Median duration of response 11.1 months 6.9 months –
12-month overall survival 63.4% 50.8% –
12-month progression-free survival 29.4% 12.4% –

Merck said sac-TMT reduced the risk of death by 32% (95% CI 0.55 to 0.84, P<0.0001) and the risk of progression or death by 41% (95% CI 0.50 to 0.70, P<0.0001). Lorusso told the meeting the curves separated early and stayed apart. Shweta Jain, a Merck vice president, said in an email before the release that these patients have a median overall survival of less than a year on current therapy, so almost seven extra months is meaningful.

Sac-TMT is the first TROP2 ADC to demonstrate an improvement in overall survival in advanced or recurrent endometrial cancer in this setting compared to chemotherapy in a global Phase 3 trial.

Domenica Lorusso, global lead investigator, ESMO Congress 2026

Health-related quality of life was maintained over time on the ADC, Merck said. Responses lasted longer as well, and complete responses were only slightly more common than on chemo.

The Survival Benefit Was Not the Same in Every Subgroup

The headline hazard ratio averages groups that did not move together. About 84.5% of patients on sac-TMT and 84.1% on chemo had mismatch-repair-proficient (pMMR) tumors, and 79.5% in each arm had medium-high Trop-2 staining. Randomization was stratified by mismatch-repair status, Trop-2 level, number of prior lines, and whether disease was measurable.

OVERALL SURVIVAL BY PRESPECIFIED SUBGROUP

Group Patients OS hazard ratio (95% CI) Favors
pMMR tumors 654 0.62 (0.49-0.78) Sac-TMT
dMMR tumors 122 0.99 (0.60-1.63) Neither clearly
Medium-high Trop-2 617 0.58 (0.45-0.74) Sac-TMT
Low Trop-2 159 1.07 (0.72-1.60) Neither clearly
Carcinosarcoma, local histology 48 2.27 (1.09-4.71) Chemo

Confirmed responses were 41.3% versus 15.9% in non-endometrioid tumors, 34.1% versus 19.1% in endometrioid tumors, and 14.8% versus 9.5% in carcinosarcoma. Central review capped carcinosarcoma at 4% of the study. Discussant Liu noted that only about one-third of those carcinosarcoma patients had high Trop-2, which may help explain a split that should be read as exploratory in a small cell. Progression-free survival followed the same pattern, with a carcinosarcoma PFS hazard ratio of 1.52 (0.80 to 2.90).

Trop-2 is overexpressed in more than 90% of endometrial cancers, which is why a Trop-2 ADC was a rational test. The low-expression slice still enrolled 159 women, and their survival ratio sat on the wrong side of 1. Any U.S. label that tracks the trial population will have to live with that scatter, not only with the 32% average.

What the Trial Showed on Safety and Dropouts

The safety profile matched earlier sac-TMT studies, Merck said, with no new signals. Almost every patient on the ADC had a treatment-related event, most of them low grade and handled with supportive care and dose changes. Dropouts were lower on sac-TMT than on chemo. Treatment-related deaths occurred in 0.8% of patients, three people, in each arm.

MAIN TREATMENT-RELATED SAFETY FINDINGS

  • Any-grade events: 97.1% on sac-TMT versus 89.6% on chemotherapy.
  • Grade 3 or higher: 54.4% versus 41.4%.
  • Severe anemia: 23.7% on the ADC, the most common high-grade clinical event.
  • Severe neutropenia: 20.1% on the ADC.
  • Severe mouth sores: 9.9% listed as oral mucositis or stomatitis.
  • Stopped for side effects: 3.1% on sac-TMT versus 4.9% on chemo.

Katy Moore, a gynecologic oncologist and deputy director of the Buffett Cancer Center, called the survival gain clinically meaningful and said it warrants use, while warning that stomatitis, eye toxicity, and anemia will need aggressive counseling. She put any-grade stomatitis at 57%, mostly low grade, and said patients will need prophylactic steroid mouthwash for stomatitis, with eye symptoms in 31% and anemia in 71%. Those any-grade rates sit beside Merck’s smaller grade 3 figures; they describe different slices of the same toxicity, not a second trial.

Bhavana Pothuri, a principal investigator and professor of obstetrics, gynecology, and medicine at NYU Grossman School of Medicine, said she has used several Trop-2 ADCs in endometrial cancer and found this one better tolerated. She also said it is the first new therapy that can be offered after immunotherapy, because the current standard in that slot is chemotherapy with poor outcomes.

Kelun Built It, and Merck Filed It in the U.S.

Sac-TMT is a Trop-2 antibody joined, through a bifunctional linker Merck calls unique, to a belotecan-derived topoisomerase I inhibitor. The average drug-to-antibody ratio is 7.4. Kelun-Biotech, a unit of Sichuan Kelun Pharmaceutical listed in Hong Kong as 6990.HK, designed the conjugate. Merck holds exclusive rights to develop, make, and sell it outside Greater China, meaning mainland China, Hong Kong, Macau, and Taiwan.

The drug is already approved in China for previously treated triple-negative breast cancer, EGFR-mutant non-small-cell lung cancer, and hormone receptor-positive metastatic breast cancer. Merck is running the Western program under the TroFuse name, with 18 global Phase 3 trials across endometrial, bladder, breast, cervical, gastric, lung, and ovarian cancers, more than 15,000 patients, and 10 of those Phase 3 studies in women’s cancers. TroFuse-005 is one of 14 trials Merck describes as first-in-class opportunities. A separate first-line study, TroFuse-033, is testing the ADC with Keytruda in pMMR endometrial cancer.

HOW THE WESTERN BET WAS ASSEMBLED

  1. 2022: Kelun grants Merck exclusive rights to sac-TMT outside Greater China, after Merck exercises an option on the Trop-2 ADC then called SKB264 or MK-2870.
  2. December 22, 2022: The companies add an exclusive license covering seven investigational antibody-drug conjugates, with $175 million upfront and up to $9.3 billion in milestones if options and approvals all land, plus tiered royalties.
  3. November 4, 2025: Funds managed by Blackstone Life Sciences agree to pay Merck $700 million, non-refundable, toward 2026 sac-TMT development costs, in return for low-to-mid single-digit royalties if the U.S. approves first-line triple-negative breast cancer based on TroFuse-011.
  4. May 2026: Merck says TroFuse-005 has met both primary endpoints at an interim analysis, with full data held for a medical meeting.
  5. October 26, 2026: Lorusso presents the numbers in Madrid; the FDA later accepts a priority-review BLA with a June 15, 2027 target date.

Dean Li, president of Merck Research Laboratories, said the company is hopeful for an approval before that PDUFA date. The application covers adults with endometrial cancer who previously received platinum chemotherapy and a PD-1 or PD-L1 inhibitor, separately or together.

Nearly Half of Merck’s 2025 Sales Sit in Keytruda

Keytruda and the newer subcutaneous form Keytruda Qlex together sold $31.68 billion in 2025, or 48.7% of Merck’s $65.01 billion in total sales, according to the company’s annual report. Merck lists the main U.S. Keytruda patent as expiring in 2028, with two further U.S. patents in 2029 and later dates in Europe and Japan. That clock is why an ADC licensed from Chengdu is being asked to do more than treat one gynecologic niche.

THE COMMERCIAL STACK BEHIND SAC-TMT

  • Keytruda 2025 sales: $31.68 billion including $40 million of Keytruda Qlex.
  • Share of Merck: 48.7% of $65.01 billion in company sales.
  • U.S. patent year: 2028 for the main Keytruda patents.
  • Sac-TMT Phase 3 load: 18 global studies, 10 of them in women’s cancers.

Merck’s own U.S. snapshot for endometrial cancer in 2026 is about 68,270 diagnoses and 14,450 deaths. The disease is the sixth most common cancer in women worldwide and the 15th most common cancer overall. Those figures justify a dedicated drug. They do not, on their own, rebuild a $31.68 billion immunotherapy line.

Blackstone’s $700 million is tied to a breast-cancer approval, not to endometrial cancer. The royalty only kicks in if TroFuse-011 wins a U.S. first-line triple-negative breast cancer nod. Endometrial cancer is the first Western survival proof. The financing still points at a larger tumor.

Gilead’s Endometrial Trop-2 Trial Is Not Due Until 2029

Sac-TMT is not the first Trop-2 ADC. Gilead’s sacituzumab govitecan, sold as Trodelvy, and AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan, sold as Datroway, are already on the U.S. market in other tumors. They are different drugs with different payloads, and they are not interchangeable with sac-TMT. Gilead’s Phase 3 endometrial study, ASCENT-GYN-01, is not expected to finish until 2029, which leaves Merck a multi-year head start in this exact post-platinum, post-PD-1 slot if the FDA agrees with TroFuse-005.

Liu, discussing the Madrid data, noted that sac-TMT is one of seven ADCs in Phase 3 for endometrial cancer, all carrying topoisomerase I inhibitor payloads. Sequencing those drugs, and deciding whether a second ADC can follow a first when the payload class overlaps, is still an open clinic problem. Pothuri said the study is practice-changing and that clinical guidelines will need to be reassessed to include sacituzumab tirumotecan if regulators concur.

For patients, the practical comparison on October 26 was not Trodelvy. It was doxorubicin or weekly paclitaxel after Keytruda-class therapy had already failed. That is a low bar, and sac-TMT cleared it on survival, not only on shrinkage. The higher grade 3 rate, especially anemia, neutropenia, and mouth sores, is the price of that clearance.

Eighteen Phase 3 Studies Still Have to Replace a Franchise

Kelun has already reported Phase 3 lung and breast wins in China, including OptiTROP-Lung06, in which sac-TMT plus Keytruda stretched median progression-free survival to 15.0 months versus 5.7 months on Keytruda plus chemo in first-line PD-L1-negative nonsquamous lung cancer. Those China studies are the blueprint Merck still has to match in global TroFuse lung and breast trials if the ADC is going to carry anything like Keytruda money. Endometrial cancer got there first because the control arm was old chemo in a post-immunotherapy gap, not because it is the largest commercial target in the 18-trial grid.

Sac-TMT demonstrated an improvement in overall survival of almost seven months for women with endometrial cancer who progress following treatment with platinum-based chemotherapy and anti-PD-1 therapy, a meaningful advancement for these women who face a median survival of less than a year with current therapies. We believe sac-TMT, with its unique bifunctional linker, can become a cornerstone for the treatment of certain patients with advanced or recurrent endometrial cancer.

Dean Y. Li, president, Merck Research Laboratories

Li’s “certain patients” line matches the subgroup table more closely than the top-line 32% figure. The gain is clearest in pMMR disease with medium or high Trop-2. It is absent in the dMMR and Trop-2-low slices as estimated so far, and it ran backward in a small carcinosarcoma group. The FDA will decide by June 15, 2027, whether that package is enough for a U.S. label, and Merck has said it hopes to get there sooner.

Disclaimer: This article is news reporting on a completed Phase 3 trial and a pending FDA review. It is for information only and is not medical advice, a treatment recommendation, or an instruction to start, stop, or switch any cancer drug. Readers facing endometrial cancer or any other diagnosis should consult a qualified oncologist or gynecologic oncologist about their own case, test results, and options. Survival figures, side-effect rates, and the June 15, 2027 review date reflect the Merck, trial, and regulator sources cited here and may change with later analyses or a final FDA action.

Harry is the editor of COVER 365, an independent publication he owns and runs, and a journalist of ten years who moved from reporting into editing. Anything the site reviews has been used before it is judged. A phone, a car, a game or a piece of travel gear is tested in ordinary conditions, its measured results are set against the maker's specification sheet, and where the two disagree the article says which one to trust and why. No product gets a verdict Harry has not earned by using it. Off the test bench, the same rule of primary evidence applies: business stories come from filings and results, science from the published paper, sports from the governing body's records, and news from statements and transcripts rather than second hand accounts. Coverage runs across technology, auto, gaming, lifestyle and travel as well as news, business, science, sports and entertainment, for readers in every part of the world. Every figure is checked before publication and corrected publicly under a stated policy when wrong. Reader mail is answered at support@cover365.in.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending